VIDEO: Two-thirds of MS patients on ocrelizumab had no disease activity for 4 years

BOSTON — The majority of patients with relapsing-remitting MS who took ocrelizumab had no evidence of disease activity for 4 years, according to a study presented at the American Academy of Neurology annual meeting.

The ENSEMBLE study recruited adult patients within 3 years of MS diagnosis, Robert A. Bermel, MD, director of the Mellen Center for Multiple Sclerosis at Cleveland Clinic, says in this Healio video.

The primary outcome measure was no evidence of disease activity (NEDA) 4 years after the last patient was enrolled. This meant no relapses, no new MRI lesions and no disability progression, Bermel said.

“Sixty-six percent of them experienced NEDA at 4 years,” he said. “This phase 3b study really contributes to the data set saying that, yes, it does look like using highly effective therapies early is a viable treatment strategy.”